Artiva Biotherapeutics, Inc.
NASDAQ: ARTV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Fred Aslan
- Employees
- 96
- Headquarters
- San Diego, United States
- IPO year
- 2024
- Market cap
- $230.4M
- Website
- https://www.artivabio.com
Loading ARTV…
Loading profile data…Frequently asked questions about ARTV
What does Artiva Biotherapeutics, Inc. (ARTV) do?
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatmen...
Where does ARTV trade?
Artiva Biotherapeutics, Inc. (ARTV) trades on the NASDAQ Global Market.
What sector is ARTV in?
Artiva Biotherapeutics, Inc. (ARTV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Artiva Biotherapeutics, Inc.?
Fred Aslan is the chief executive officer of Artiva Biotherapeutics, Inc. (ARTV).
Where is Artiva Biotherapeutics, Inc. headquartered?
Artiva Biotherapeutics, Inc. is headquartered in United States.
Does ARTV pay a dividend?
Artiva Biotherapeutics, Inc. (ARTV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ARTV go public?
Artiva Biotherapeutics, Inc. (ARTV) completed its initial public offering in 2024.